Frontlight ResearchEarly access
CompletedPhase 2/3
COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)
Key facts
- Who runs it
- Bassett Healthcare
- Where
- Cooperstown, Portland, and Springfield, United StatesSee the 3 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2/3
- People taking part
- 15 people enrolled
- Started
- 3 Apr 2020
- Ended
- 1 Oct 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Baloxavir
- Placebos
- Record updated
- 14 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Adults >/= 18 years old
- Laboratory confirmed influenza A and/or B (rapid test or PCR)
- Able to be enrolled, randomized, and dosed with study drug within 8 hours of the decision to admit patient to hospital for treatment of influenza
- Oseltamivir treatment ordered by clinical team AND patient is able to be enrolled:; Prior to the initial dose of oseltamivir OR; Within 60 minutes after the initial dose of oseltamivir
- Subject or Legally Authorized Representative able to and willing to provide written informed consent
- Able to commit to 30 days of follow up
- Weight > 40 kg
- SARS-CoV-2 PCR swab sent within 1 week of enrollment
Who cannot take part
- Influenza medication use within the prior week, other than the initial oseltamivir given during this hospitalization for this episode of influenza
- Refusal of oseltamivir therapy by patient as baseline treatment
- Severe hepatic insufficiency, cirrhosis, acute or chronic liver failure
- Nausea/vomiting, aspiration risk, or other conditions precluding the ability to use oral medications (if patient is NPO including meds, otherwise unable to swallow oral medications)
- Oseltamivir or baloxavir allergy or intolerance
- Pregnancy (need negative pregnancy test (urine or blood) in reproductive age women)
- Absence of dependable contraception in reproductive age women
- ESRD not undergoing hemodialysis (HD) or peritoneal dialysis (CAPD)
- Inability to obtain informed consent
Where in United States
- Bassett Medical CenterCooperstown, United States
- Oregon Health Science UniversityPortland, United States
- Baystate Medical CenterSpringfield, United States
About the trial
What the trial wants to find out
This is a randomized, double-blind, placebo-controlled Phase 2-like, investigator-directed trial of hospitalized patients with laboratory confirmed influenza. Eligible and consented patients will be randomly assigned, in a 1:1 ratio, to one of two groups: Group 1, the combination treatment group (oseltamivir and baloxavir); Group 2, the standard treatment group (oseltamivir and placebo).
The 2 groups in the trial
- baloxavirTreatment being tested
Baloxavir: 40 mg po once for wt \< 80 kg OR 80 mg po once for wt \>/= 80 kg
- placeboPlacebo, for comparison
placebo po once
Treatment: Placebos
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 14 May 2026